Baidu
map

肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

CLIN CANCER RES：Entinostat在接受大剂量IL2治疗的肾细胞癌患者中的免疫调节作用

2017-12-02 MedSci MedSci原创

肾细胞癌entinostatIL2
关注

临床前实验数据表明Ⅰ类选择性HDAC抑制剂Entinostat联合大剂量IL2在肾细胞癌模型中具有协同性的抗肿瘤作用，其机制为下调Foxp3表达和抑制Treg细胞功能。CLIN CANCER RES近期报道了一个临床试验结果，评估Entinostat联合大剂量IL2治疗转移性透明细胞肾癌患者的疗效。

临床前实验数据表明Ⅰ类选择性HDAC抑制剂Entinostat联合大剂量IL2在肾细胞癌模型中具有协同性的抗肿瘤作用，其机制为下调Foxp3表达和抑制Treg细胞功能。CLIN CANCER RES近期报道了一个临床试验结果，评估Entinostat联合大剂量IL2治疗转移性透明细胞肾癌患者的疗效。

试验主要的纳入标准为病理确诊透明细胞肾癌，未接受过治疗以及适合接受大剂量IL2治疗。研究包括两个剂量水平的Entinostat（3和5mg，每14天口服）以及标准剂量的IL2（600000 U/kg，i.v.）。85天1个周期。主要的研究终点是反应率和毒性，次要的研究终点包括无进展生存和总生存。研究共纳入47例患者。平均随访时间21.9个月，反应率为37%，平均无进展生存期为13.8个月，平均总生存为65.3个月。最常见的3/4级毒性反应为低磷血症（16%），淋巴细胞减少（15%）和低钙血症（7%），所有的毒性反应均持续时间较短。在接受Entinostat治疗的患者中观察到Treg细胞下降，下降数量与治疗反应相关。

文章最后认为，该临床试验表明Entinostat联合大剂量IL2在ccRCC患者中有良好的临床疗效且为表观遗传学药物与免疫治疗的合理结合提供了范例。

原始出处：

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1978614, encodeId=876c19e861440, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Fri Jul 06 20:25:00 CST 2018, time=2018-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267863, encodeId=d68126e8633a, content=好好好学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Fri Dec 08 17:46:40 CST 2017, time=2017-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578677, encodeId=2b9615e8677ac, content=<a href='/topic/show?id=fbf0436148a' target=_blank style='color:#2F92EE;'>#大剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43614, encryptionId=fbf0436148a, topicName=大剂量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6a16418535, createdName=ms7899726347904398, createdTime=Sun Dec 03 23:25:00 CST 2017, time=2017-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266152, encodeId=0d3b266152e2, content=学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好！, createdTime=Sat Dec 02 09:48:27 CST 2017, time=2017-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266135, encodeId=eef0266135fa, content= 学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM6P57Bs8gOPaY1cQP9lIia0lmZOEXraGaoicqNToIslXDKw/0, createdBy=7a041951742, createdName=衣带渐宽, createdTime=Sat Dec 02 08:52:47 CST 2017, time=2017-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266134, encodeId=bdd72661344f, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf3f1954203, createdName=1e11f6a6m77(暂无匿称), createdTime=Sat Dec 02 08:49:15 CST 2017, time=2017-12-02, status=1, ipAttribution=)]
    2018-07-06 qingting

    #细胞癌#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1978614, encodeId=876c19e861440, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Fri Jul 06 20:25:00 CST 2018, time=2018-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267863, encodeId=d68126e8633a, content=好好好学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Fri Dec 08 17:46:40 CST 2017, time=2017-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578677, encodeId=2b9615e8677ac, content=<a href='/topic/show?id=fbf0436148a' target=_blank style='color:#2F92EE;'>#大剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43614, encryptionId=fbf0436148a, topicName=大剂量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6a16418535, createdName=ms7899726347904398, createdTime=Sun Dec 03 23:25:00 CST 2017, time=2017-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266152, encodeId=0d3b266152e2, content=学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好！, createdTime=Sat Dec 02 09:48:27 CST 2017, time=2017-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266135, encodeId=eef0266135fa, content= 学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM6P57Bs8gOPaY1cQP9lIia0lmZOEXraGaoicqNToIslXDKw/0, createdBy=7a041951742, createdName=衣带渐宽, createdTime=Sat Dec 02 08:52:47 CST 2017, time=2017-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266134, encodeId=bdd72661344f, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf3f1954203, createdName=1e11f6a6m77(暂无匿称), createdTime=Sat Dec 02 08:49:15 CST 2017, time=2017-12-02, status=1, ipAttribution=)]
    2017-12-08 zwjnj2

    好好好学习学习学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1978614, encodeId=876c19e861440, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Fri Jul 06 20:25:00 CST 2018, time=2018-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267863, encodeId=d68126e8633a, content=好好好学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Fri Dec 08 17:46:40 CST 2017, time=2017-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578677, encodeId=2b9615e8677ac, content=<a href='/topic/show?id=fbf0436148a' target=_blank style='color:#2F92EE;'>#大剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43614, encryptionId=fbf0436148a, topicName=大剂量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6a16418535, createdName=ms7899726347904398, createdTime=Sun Dec 03 23:25:00 CST 2017, time=2017-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266152, encodeId=0d3b266152e2, content=学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好！, createdTime=Sat Dec 02 09:48:27 CST 2017, time=2017-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266135, encodeId=eef0266135fa, content= 学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM6P57Bs8gOPaY1cQP9lIia0lmZOEXraGaoicqNToIslXDKw/0, createdBy=7a041951742, createdName=衣带渐宽, createdTime=Sat Dec 02 08:52:47 CST 2017, time=2017-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266134, encodeId=bdd72661344f, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf3f1954203, createdName=1e11f6a6m77(暂无匿称), createdTime=Sat Dec 02 08:49:15 CST 2017, time=2017-12-02, status=1, ipAttribution=)]
    2017-12-03 ms7899726347904398

    #大剂量#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1978614, encodeId=876c19e861440, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Fri Jul 06 20:25:00 CST 2018, time=2018-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267863, encodeId=d68126e8633a, content=好好好学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Fri Dec 08 17:46:40 CST 2017, time=2017-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578677, encodeId=2b9615e8677ac, content=<a href='/topic/show?id=fbf0436148a' target=_blank style='color:#2F92EE;'>#大剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43614, encryptionId=fbf0436148a, topicName=大剂量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6a16418535, createdName=ms7899726347904398, createdTime=Sun Dec 03 23:25:00 CST 2017, time=2017-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266152, encodeId=0d3b266152e2, content=学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好！, createdTime=Sat Dec 02 09:48:27 CST 2017, time=2017-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266135, encodeId=eef0266135fa, content= 学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM6P57Bs8gOPaY1cQP9lIia0lmZOEXraGaoicqNToIslXDKw/0, createdBy=7a041951742, createdName=衣带渐宽, createdTime=Sat Dec 02 08:52:47 CST 2017, time=2017-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266134, encodeId=bdd72661344f, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf3f1954203, createdName=1e11f6a6m77(暂无匿称), createdTime=Sat Dec 02 08:49:15 CST 2017, time=2017-12-02, status=1, ipAttribution=)]
    2017-12-02 明天会更好！

    学习了.谢谢分享!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1978614, encodeId=876c19e861440, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Fri Jul 06 20:25:00 CST 2018, time=2018-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267863, encodeId=d68126e8633a, content=好好好学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Fri Dec 08 17:46:40 CST 2017, time=2017-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578677, encodeId=2b9615e8677ac, content=<a href='/topic/show?id=fbf0436148a' target=_blank style='color:#2F92EE;'>#大剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43614, encryptionId=fbf0436148a, topicName=大剂量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6a16418535, createdName=ms7899726347904398, createdTime=Sun Dec 03 23:25:00 CST 2017, time=2017-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266152, encodeId=0d3b266152e2, content=学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好！, createdTime=Sat Dec 02 09:48:27 CST 2017, time=2017-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266135, encodeId=eef0266135fa, content= 学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM6P57Bs8gOPaY1cQP9lIia0lmZOEXraGaoicqNToIslXDKw/0, createdBy=7a041951742, createdName=衣带渐宽, createdTime=Sat Dec 02 08:52:47 CST 2017, time=2017-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266134, encodeId=bdd72661344f, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf3f1954203, createdName=1e11f6a6m77(暂无匿称), createdTime=Sat Dec 02 08:49:15 CST 2017, time=2017-12-02, status=1, ipAttribution=)]
    2017-12-02 衣带渐宽

    学习

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1978614, encodeId=876c19e861440, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Fri Jul 06 20:25:00 CST 2018, time=2018-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267863, encodeId=d68126e8633a, content=好好好学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Fri Dec 08 17:46:40 CST 2017, time=2017-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578677, encodeId=2b9615e8677ac, content=<a href='/topic/show?id=fbf0436148a' target=_blank style='color:#2F92EE;'>#大剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43614, encryptionId=fbf0436148a, topicName=大剂量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6a16418535, createdName=ms7899726347904398, createdTime=Sun Dec 03 23:25:00 CST 2017, time=2017-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266152, encodeId=0d3b266152e2, content=学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好！, createdTime=Sat Dec 02 09:48:27 CST 2017, time=2017-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266135, encodeId=eef0266135fa, content= 学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM6P57Bs8gOPaY1cQP9lIia0lmZOEXraGaoicqNToIslXDKw/0, createdBy=7a041951742, createdName=衣带渐宽, createdTime=Sat Dec 02 08:52:47 CST 2017, time=2017-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=266134, encodeId=bdd72661344f, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf3f1954203, createdName=1e11f6a6m77(暂无匿称), createdTime=Sat Dec 02 08:49:15 CST 2017, time=2017-12-02, status=1, ipAttribution=)]
    2017-12-02 1e11f6a6m77(暂无匿称)

    学习学习

    0

相关资讯

Oncotarget：一种肾透明细胞癌的非侵入性生物标志物，miR-210-3p。

肾透明细胞癌（ccRCC）是肾细胞癌（RCC）最常见的亚型。占所有肾恶性肿瘤的70-80％，是前列腺和膀胱癌后第三大泌尿系癌症。鉴定出有助于ccRCC的诊断和判断治疗反应的非侵入性生物标志物可能代表ccRCC管理中的重要进步。

Sci Rep：原位肾细胞癌异种移植模型实验成像比较分析

最近，有研究人员在原位肾细胞癌（RCC）异种种植模型中比较性的评估了高分辨率3D超声波扫描成像（hrUS）、体内显微CT（μCT）和9.4TMRI技术对肿瘤生长的监控情况，并且目前还没有一种确定的和非侵入性的成像工具来实现上述目的。研究人员将1×106 Caki-2 RCC细胞移植到16只免疫缺陷小鼠的肾包膜上，并利用hrUS、μCT和MRI检查对局部的和全身的肿瘤生长进行监控。细胞移植到了所有的

ANN ONCOL：CRLX101联合贝伐单抗与标准疗法比较治疗晚期肾细胞癌

纳米药物可以增强向肿瘤转运药物的能力。肿瘤细胞内渐进的有效药物浓度释放可以增强抗肿瘤活性同时降低毒性。CRLX101是一种含有喜树碱的理想纳米药物，喜树碱是异构酶Ⅰ和缺氧诱导因子1α和2α的抑制剂。在Ⅰb/2期临床试验中，CRLX101联合贝伐单抗在治疗转移性肾细胞癌中耐受性良好且可以增强抗肿瘤活性。ANN ONCOL近期发表了一篇文章，报道CRLX101+贝伐单抗与标准治疗（SOC）相比治疗复发

ESMO Asia 2017：舒尼替尼的个体化治疗

在2017年ESMO Asia和ESMO会议上，分别有两项研究评估了舒尼替尼个体化治疗方案在亚洲患者和中国患者的疗效和安全性。

Mol Cancer：研究揭示LncRNA RP11-436H11.5促进肾细胞癌增殖和侵袭的机制

来越多的证据表明，长链非编码RNAs（lncRNAs）在肿瘤发生中起着至关重要的作用。本研究中，研究人员报告了一种新型lncRNA，RP11-436H11.5，通过海绵miR-335-5p调节肾细胞癌（RCC）的细胞增殖和侵袭。通过qRT-PCR测定RCC组织中的lncRNA RP11-436H11.5的表达。通过细胞增殖测定和transwell侵袭测定来测量RCC细胞的增殖和侵袭。通过蛋白质印迹

Sci Rep：非内脏肥胖肾细胞癌病人异位肝脂质积累的临床意义

脂肪肝已经成为了癌症的预后标记，因此，最近有研究人员调查了肝脏中异位肝脂质积累对患有肾细胞癌（RCC）病人临床结果的影响。研究人员回顾了230名连续病人的医疗记录，这些病人经历了RCC外科手术治疗，并且在手术前的平扫CT成像中从衰减信号中评估了肝脏脂肪积累。研究人员发现，G3肿瘤病人的肝脏CT平均值要比G1-2肿瘤病人更低（P=0.0116）；pT3-4病人肿瘤的肝脏CT平均值要比pT1-2肿瘤病

Baidu
map
Baidu
map
Baidu
map